Dong Xi Selected Research

Massive Hepatic Necrosis

1/2022	Fibrinogen-like protein 2 deficiency inhibits virus-induced fulminant hepatitis through abrogating inflammatory macrophage activation.
1/2018	Clara Cell 10 kDa Protein Alleviates Murine Hepatitis Virus Strain 3-Induced Fulminant Hepatitis by Inhibiting Fibrinogen-Like Protein 2 Expression.
1/2017	IL-33 protects murine viral fulminant hepatitis by targeting coagulation hallmark protein FGL2/fibroleukin expression.
1/2013	Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice.
11/2011	[KCTD9, a novel potassium channel related gene, was highly expressed in hepatic NK cells and T cells of fulminant hepatitis mice induced by MHV-3].
8/2010	Dual interference with novel genes mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
2/2010	Construction of mTNFR1shRNA plasmid and its biological effects on MHV-3 induced fulminant hepatitis in BALB/cJ mice.
12/2008	[Construction of p-hfgl2shRNA and its effect on hfgl2 expression in vitro].
6/2006	Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
11/2005	Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dong Xi Research Topics

Disease

11	Hepatitis 04/2016 - 07/2004
10	Massive Hepatic Necrosis 01/2022 - 11/2005
8	Necrosis 01/2018 - 07/2004
5	Chronic Hepatitis B 01/2022 - 11/2005
4	Neoplasms (Cancer) 01/2021 - 10/2008
4	Fibrosis (Cirrhosis) 01/2020 - 07/2004
4	Infections 01/2018 - 11/2005
4	Hepatitis B 11/2008 - 03/2003
3	Hepatocellular Carcinoma (Hepatoma) 08/2019 - 11/2012
3	Schizophrenia (Dementia Praecox) 05/2011 - 01/2009
2	Inflammation (Inflammations) 01/2020 - 01/2017
2	Non-alcoholic Fatty Liver Disease 01/2020 - 12/2019
2	Autoimmune Hepatitis 01/2018 - 12/2006
2	Asthma (Bronchial Asthma) 01/2018 - 01/2004
2	Acute Liver Failure (Fulminant Hepatic Failure) 01/2013 - 09/2009
2	Chronic Hepatitis (Chronic Active Hepatitis) 11/2011 - 07/2004
2	Hepatitis A (Hepatitis, Infectious) 08/2010 - 06/2006
1	Reperfusion Injury 06/2021
1	Liver Diseases (Liver Disease) 06/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Leukemia 01/2021
1	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 01/2020
1	Obesity 01/2020
1	Insulin Resistance 01/2020
1	Clostridium Infections 12/2019
1	Ulcerative Colitis 12/2019
1	Hirschsprung Disease (Hirschsprung's Disease) 11/2019
1	Intestinal Failure 11/2019
1	Weight Loss (Weight Reduction) 11/2019
1	Virus Diseases (Viral Diseases) 01/2018
1	Allergic Rhinitis 01/2018
1	Genomic Instability 03/2017
1	Carcinogenesis 10/2014
1	Hyperoxia 10/2012
1	Melanoma (Melanoma, Malignant) 10/2012
1	Body Weight (Weight, Body) 11/2010
1	Mental Disorders (Mental Disorder) 01/2009

Drug/Important Bio-Agent (IBA)

17	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2003
14	Fibrinogen (Factor I)FDA Link 01/2022 - 07/2004
6	FibrinIBA 01/2018 - 07/2004
6	Thromboplastin (Tissue Factor)IBA 08/2010 - 07/2004
5	Messenger RNA (mRNA)IBA 11/2011 - 03/2003
3	CytokinesIBA 01/2020 - 10/2008
3	DNA (Deoxyribonucleic Acid)IBA 03/2017 - 10/2007
3	MicroRNAs (MicroRNA)IBA 07/2016 - 10/2012
3	gamma-Aminobutyric Acid (GABA)IBA 11/2010 - 01/2009
2	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 01/2021
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2022 - 01/2021
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 09/2009
2	CoagulantsIBA 01/2018 - 01/2017
2	Biological ProductsIBA 11/2012 - 02/2010
2	Potassium Channels (Potassium Channel)IBA 11/2011 - 11/2008
2	Type I Tumor Necrosis Factor ReceptorsIBA 08/2010 - 02/2010
2	Small Interfering RNA (siRNA)IBA 08/2010 - 05/2006
2	Pharmaceutical PreparationsIBA 09/2009 - 01/2006
2	Transcription Factors (Transcription Factor)IBA 11/2008 - 07/2008
1	GTP-Binding Proteins (G-Protein)IBA 06/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 06/2021
1	Bile Acids and Salts (Bile Acids)IBA 06/2021
1	Long Noncoding RNAIBA 01/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Circular DNAIBA 01/2021
1	ChemokinesIBA 01/2021
1	AnkyrinsIBA 01/2021
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	FructoseIBA 01/2020
1	EnzymesIBA 01/2020
1	InflammasomesIBA 01/2020
1	rebaudioside AIBA 01/2020
1	Drinking WaterIBA 01/2020
1	Sucrose (Saccharose)IBA 01/2020
1	trichlorosucrose (sucralose)IBA 01/2020
1	Sweetening Agents (Sweeteners)IBA 12/2019
1	Interleukin-6 (Interleukin 6)IBA 08/2019
1	InterleukinsIBA 08/2019
1	AutoantigensIBA 01/2018
1	Interleukin-33IBA 01/2017
1	BilirubinIBA 04/2016
1	Alanine Transaminase (SGPT)IBA 04/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2016
1	InterferonsIBA 10/2014
1	Therapeutic UsesIBA 01/2013
1	Glycoproteins (Glycoprotein)IBA 10/2012
1	IgA receptor (protein B)IBA 10/2012
1	Antipsychotic Agents (Antipsychotics)IBA 05/2011
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2011
1	Dizocilpine Maleate (Dizocilpine)IBA 05/2011
1	metabotropic glutamate receptor 2IBA 05/2011
1	Phosphates (Orthophosphate)IBA 11/2010
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 08/2010
1	N-Methylaspartate (NMDA)IBA 11/2009
1	GalactosamineIBA 09/2009
1	Galactose (Galactopyranose)FDA LinkGeneric 09/2009

Therapy/Procedure

4	Transplantation 11/2019 - 05/2006
2	Organ Transplantation 08/2010 - 06/2006
1	Hepatectomy 06/2021
1	Therapeutics 12/2019
1	Fecal Microbiota Transplantation 12/2019
1	Ostomy 11/2019